YILING PHARMACEUTICAL(SZ:002603) Xuan Gu Bao·2025-11-12 12:00Suspension and Resumption - ST Zhongdi: Stock suspended for investigation due to abnormal trading fluctuations [1] Share Buyback - Century Huatong: Plans to repurchase shares worth between 500 million to 1 billion yuan for capital reduction [2] Investment Cooperation and Operational Status - Yiling Pharmaceutical: Subsidiary's application for hydrochloride memantine raw material approved for treating moderate to severe Alzheimer's disease [3] - Changrong Co.: Collaborating with Jinchang Investment to establish a project company for a 100 MW photovoltaic power station [4] - Wanjian Medical: Subsidiary plans to invest 2 billion yuan to build a cotton non-woven fabric production base [4] - Haibo Sichuang: Signed a strategic cooperation agreement with CATL to procure no less than 200 GWh of electricity from 2026 to 2028 [4] - Shengtun Mining: Plans to increase investment of 1.423 billion yuan in its wholly-owned subsidiary Shengtun Gold International [5] - Yahua Group: Achieved progress in solid-state battery field with a new process for synthesizing lithium sulfide [6] - Haiguo Co.: Plans to establish a holding subsidiary for high-end components projects including flywheel energy storage [7] Performance Changes - BeiGene: Reported a net profit of 1.139 billion yuan in the first three quarters, turning a profit compared to the previous year [8]